Comparison of the clinical features and clinical course of antimitochondrial antibody‐positive and ‐negative primary biliary cirrhosis
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Reports from North America and Northern Europe have suggested that antimitochondrial antibody (AMA) negative primary biliary cirrhosis (PBC) is a distinct chronic cholestatic liver disease with high prevalence of serum non-organ-specific autoantibodies other than AMA. To evaluate if such a peculiar serum immunoreactivity is associated with clinically relevant characteristics, we reviewed our experience with 297 Italian patients who have had a clinical and histological diagnosis of PBC and were regularly followed-up at our Center from June 1974 to June 1994. AMA-negative and AMA-positive patients were compared in terms of biochemical and clinical features, and clinical outcome of the disease. At presentation, 30 of 297 patients (10%) tested negative for AMA by indirect immunofluorescence. Six of them tested positive for antimitochondrial M2 antibodies (AMA-M2) by immunoblotting analysis, therefore, diagnosis of AMA-negative PBC was made in 24 patients (8%). At the initial visit, AMA-negative and AMA-positive patients were similar in terms of biochemical and clinical features. Antinuclear and anti-smooth-muscle antibodies (ANA and ASMA) were more frequently positive in the AMA-negative patients (71% vs. 31%, and 37% vs. 9%; both P = .0002). Incidence of complications of cirrhosis and development of liver failure resulting in death or referral for liver transplantation did not differ significantly between the two populations. In conclusion, data from this historical cohort study suggest that the distinct serological features of AMA-negative PBC are not associated with substantial differences in the clinical spectrum or course of the disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although AMA-negative PBC patients are nearly identical to AMA-positive PBC patients, minor differences have been noted, including a higher prevalence of antinuclear and anti-smooth muscle antibodies and lower serum IgM levels.(111)(112)(113)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [113]
In the citing paper
“However, treatment response to UDCA appears similar in AMA-negative and AMA-positive PBC patients, and whether there are differences in clinical outcomes has not been resolved.(113,115)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [113]
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,385
Kaplan, M. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198702263160907 · Cited by 1,959
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
(1959) · Postgraduate Medical Journal · doi:10.1136/pgmj.45.522.305-d · Cited by 497
Michieletti, P., Wanless, I. R., Katz, A., Scheuer, P. J., Yeaman, S. J., Bassendine, M. F., Palmer, J. M., & Heathcote, E. J. (1994) · Gut · doi:10.1136/gut.35.2.260 · Cited by 236
Autoimmune cholangiopathy: Part of the spectrum of autoimmune chronic active hepatitis
Ben-Ari, Z., Dhillon, A. P., & Sherlock, S. (1993) · Hepatology · doi:10.1002/hep.1840180103 · Cited by 218
Primary biliary cirrhosis: Paradigm or paradox for autoimmunity
Gershwin, M. E., & Mackay, I. R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)80033-6 · Cited by 206
Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity
Lenzi, M., Ballardini, G., Bianchi, F. B., Johnson, P. J., McFarlane, I. G., Smith, H. M., McFarlane, B. M., Bridger, C., Williams, R., & Vergani, D. (1991) · The Lancet · doi:10.1016/0140-6736(91)90418-o · Cited by 200
Antimitochondrial antibody-negative primary biliary cirrhosis.
Lacerda, M. A., Ludwig, J., Dickson, E. R., Jorgensen, R. A., & Lindor, K. (1995) · PubMed · Cited by 196
Cited by
Items 201–294 of 294
Tsou, Y., & Yeh, C. (2003) · PubMed · Cited by 7
Alfano, A., Romito, A., Marchese, C. A., Battistini, M., Crotti, G., Ferrini, A., Mancinetti, C., Manetta, T., Mengozzi, G., Merlach, P., et al. (2016) · Immunologic Research · doi:10.1007/s12026-016-8838-2 · Cited by 7
“Until today, there is no real evidence of its utility in disease follow-up seeing no correlation between its titer and the severity of the disease [14, 15].”
BackgroundCase Report: Treatment of Autoimmune Cholangitis
Mohr, L., Heintges, T., Hensel, F., Niederau, C., & Häussinger, D. (1998) · Digestive Diseases and Sciences · doi:10.1023/a:1018840105188 · Cited by 7
S100A12 expression in patients with primary biliary cirrhosis
Ma, D., Li, X., Zhang, L., Deng, C., Zhang, T., Wang, L., Hu, C., Li, Y., & Zhang, F. (2014) · Immunological Investigations · doi:10.3109/08820139.2014.914530 · Cited by 6
Primary Biliary Cholangitis: A Review
Xu, H. Z., & Yanny, B. (2022) · Gene Expression · doi:10.14218/gejlr.2022.00013 · Cited by 7
Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature
Smyk, D. S., Bogdanos, D. P., Parés, A. R., Liaskos, C., Billinis, C., Burroughs, A. K., & Rigopoulou, E. I. (2012) · Tuberculosis Research and Treatment · doi:10.1155/2012/218183 · Cited by 6
“Only 3–10% of patients with PBC lack these antibodies and are considered true AMA-negative PBC patients [28, 34–37].”
BackgroundMapping of a disease susceptibility locus in the HLA region for Primary Biliary Cirrhosis in Japan
Yahagi, K., Ueno, Y., Nomura, E., Fukushima, K., Moritoki, Y., Kogure, T., Kojima, Y., Negoro, K., Kinouchi, Y., & Shimosegawa, T. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00031.x · Cited by 7
The variant forms of cholestatic diseases involving small bile ducts in adults
Chazouillères, O. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80437-7 · Cited by 6
Familial primary biliary cirrhosis and autoimmune cholangitis
Agarwal, K., Jones, D. E. J., Watt, F. E., Burt, A. D., Floreani, A., & Bassendine, M. F. (2002) · Digestive and Liver Disease · doi:10.1016/s1590-8658(02)80059-7 · Cited by 6
Vierling, J. M. (1999) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70085-4 · Cited by 6
Primary biliary cholangitis: Diagnosis and treatment
Chew, M. T., & Bowlus, C. L. (2018) · Liver Research · doi:10.1016/j.livres.2018.03.004 · Cited by 6
Selmi, C. F., & Gershwin, M. E. (2008) · Humana Press eBooks · doi:10.1007/978-1-60327-285-8_55 · Cited by 5
Mayo, M. J., Lipsky, P. E., Miller, S. N., Šťastný, P., & Combes, B. (2001) · Digestive Diseases and Sciences · doi:10.1023/a:1005609100900 · Cited by 5
Late-Onset Autoimmunity: The Paradigm of Primary Biliary Cirrhosis – A Mini-Review
Siegel, S. M., Selmi, C. F., Dottorini, L., Antelmi, M., Zuin, M. G., Lanfredini, M., & Gershwin, M. E. (2008) · Gerontology · doi:10.1159/000138335 · Cited by 6
“although the lack of a detectable serum AMA does not have significance in the disease natural history [”
BackgroundSelf-citationClark, V., & Levy, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_3 · Cited by 5
Invernizzi, P., Selmi, C. F., & Gershwin, M. E. (2007) · Elsevier eBooks · doi:10.1016/b978-044452763-9/50063-9 · Cited by 5
Self-citationInvernizzi, P., Leung, P. S. C., Ma, X., & Gershwin, M. E. (2013) · Springer eBooks · doi:10.1007/978-3-319-02096-9_18 · Cited by 5
Self-citationIshibashi, H. (2001) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2001.02408.x · Cited by 5
Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets
Mimura, S., Morishita, A., Oura, K., Yano, R., Nakahara, M., Tadokoro, T., Fujita, K., Tani, J., Tatsuta, M., Himoto, T., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238503 · Cited by 4
“Although the clinical presentation and treatment response are generally similar to AMA-positive cases [95], delayed diagnosis may contribute to poorer outcomes [96].”
Feng, L., Dong, K., Zhang, X., Ma, B., Chen, L., Yang, Q., Chen, Q., Wen, X., & Jin, Q. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242164 · Cited by 4
“Furthermore, IgG-M2 levels did not change significantly during UDCA treatment, which was in line with the results of Invernizzi [29] and Benson [30].”
ResultPeters, M. G. (1998) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70005-2 · Cited by 4
Coeliac disease and autoimmune cholangitis: a case report
Marignani, M., Angeletti, S., Mari, T., D'Alessandro, P., Palumbo, P., Dato, A., & Zullo, A. (2002) · Digestive and Liver Disease · doi:10.1016/s1590-8658(02)80257-2 · Cited by 4
Talwalkar, J. A., & Lindor, K. D. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50046-2 · Cited by 4
Colchicine for primary biliary cirrhosis
Gong, Y., & Gluud, C. N. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004481 · Cited by 4
Methotrexate for primary biliary cirrhosis
Gong, Y., & Gluud, C. N. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004385 · Cited by 4
Chatzipantelis, P., & Giatromanolaki, A. N. (2021) · PubMed · doi:10.1097/meg.0000000000001876 · Cited by 3
Selmi, C. F., Coppel, R. L., & Gershwin, M. E. (2006) · Elsevier eBooks · doi:10.1016/b978-012595961-2/50057-3 · Cited by 4
Bergasa, N. V. (2021) · Springer eBooks · doi:10.1007/978-1-4471-4715-2_3 · Cited by 5
Distinction between Mitochondrial Antibody-Positive and -Negative Primary Biliary Cholangitis
Matli, V. V. K., Dies, D. F., Pandit, S., Wellman, G., & Morris, J. (2023) · Case Reports in Gastroenterology · doi:10.1159/000528437 · Cited by 4
“Up to 5% of PBC patients lack these antibodies but 5 – 10% Low [11] Low [11] 96% (higher prevalence and higher titers than AMA-pos patients) [12] Other PBC-speci fi c autoantibodies Anti-HK-1 and anti-Kelch-12 antibodies are present in 40% of cases.”
BackgroundOverlap Syndromes with Autoimmune Hepatitis
Smith, A. D. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-118-5_5 · Cited by 3
“Two earlier studies reported no significant differences in response to treatment with UDCA or requirement for OLT among patients with PBC according to their AMA status ( 15 ,32).”
BackgroundDancygier, H. (2009) · Springer eBooks · doi:10.1007/978-3-642-04519-6_20 · Cited by 3
Beuers, U. H., & Rust, C. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-518-3_23 · Cited by 3
Miyakawa, H., Kawaguchi, N., Kikuchi, K., Fujikawa, H., Kitazawa, E., & Matsushita, M. (2001) · Hepatology Research · doi:10.1016/s1386-6346(01)00098-5 · Cited by 3
Sebode, M., Bantel, H., Baumann, U., Bufler, P., Demir, M., Dold, L., Keitel, V., Klein, R., Kremer, A. E., Jansen, P. L., et al. (2026) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2769-2475 · Cited by 2
Mayo, M. J., & Thiele, D. L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch100 · Cited by 4
Tanaka, A., & Gershwin, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00058-0 · Cited by 2
Yahia, A., Baker, F. A., Tatour, M., & Hazzan, R. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.102147 · Cited by 2
Nguyen-Khac, É., Kairis, L., Gournay, N., Bonnière, M., Thévenot, T., Mathurin, P., HACHULLA, E., Paris, J.-C., & Dupas, J. (2004) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(04)95189-5 · Cited by 2
“Les cholangites auto-immunes sont en fait une forme particulière de CBP séronégative, dont elles partagent l’aspect cholestatique et le profil évolutif [36-40].”
BackgroundWashington, M. K. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3966-2.00027-8 · Cited by 2
Sclair, S. N., & Levy, C. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-37591-7.00042-2 · Cited by 3
Levy, C., Carrion, A. F., & Mayo, M. J. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch21 · Cited by 2
Biologie des Maladies Cholestatiques Chroniques de l' Adulte
Chazouillères, O. (2007) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(07)80301-7 · Cited by 2
Primary biliary cirrhosis with features of autoimmune hepatitis
Heathcote, J. (2001) · Current Gastroenterology Reports · doi:10.1007/s11894-001-0042-3 · Cited by 2
“Subsequently, other authors described very similar patient populations [29, 30 ].”
BackgroundPrimary Biliary Cirrhosis and Autoimmune Cholangitis
Selmi, C. F., Lleò, A., Invernizzi, P., & Gershwin, M. E. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-518-3_19 · Cited by 2
“Moreover, patients lacking detectable AMAs, (especially when indirect immunofluorescence is used) but otherwise presenting signs of PBC should be regarded as affected by “AMA-negative PBC” (or autoimmune cholangitis), as they appear to follow a similar natural history compared with their AMA-positive counterparts ( 6…”
ResultSelf-citationLiver Involvement in Sjögren’s Syndrome
Fragoulis, G., Skopouli, F. N., Selmi, C. F., & Gershwin, M. E. (2011) · Springer eBooks · doi:10.1007/978-0-85729-947-5_17 · Cited by 4
Chlorambucil for primary biliary cirrhosis
Li, W. X., Gou, J. F., Yan, X., Shi, C. R., Zhang, A. P., & Sui, J. H. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008714 · Cited by 2
Overlap syndromes from pediatrics to adulthood
Bogdanos, D. P., Vergani, D., & Mieli‐Vergani, G. (2004) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2004.03688.x · Cited by 2
Rinella, M. E. (2006) · Annals of Hepatology · doi:10.1016/s1665-2681(19)32010-1 · Cited by 2
“In fact, the natural history of patients with or without a positive AMA is no different, suggesting it does not have a predominant pathogenetic role.(11)”
BackgroundPrimary biliary cirrhosis in Lithuania: diagnosis and clinical picture.
Speičienė, D., Irnius, A., Leuschner, U., Liakina, V., Semuchiniene, T., & Barakauskienė, A. (2007) · PubMed · Cited by 2
Inflammatory hepatobiliary cirrhosis
Selmi, C. F., Manns, M. P., & Gershwin, M. E. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04404-2.10075-2 · Cited by 2
Cyclosporin A for primary biliary cirrhosis
Gong, Y., Christensen, E., & Gluud, C. N. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005526 · Cited by 2
Primary biliary cholangitis, a rising health burden
Elnaggar, M., Elkhattib, I., Abomhya, A., & Boyer, J. L. (2024) · Exploration of Immunology · doi:10.37349/ei.2024.00165 · Cited by 1
Selmi, C. F., Ceribelli, A., & Gershwin, M. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-444-56378-1.00057-5 · Cited by 1
Trivella, J. P., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-26710-9.00018-3 · Cited by 1
Pathology of the Intrahepatic and Extrahepatic Bile Ducts and Gallbladder
Washington, K. M. (2006) · Wiley eBooks · doi:10.1002/9780470986981.ch2 · Cited by 1
Answers to Multiple Choice Questions
Agrawal, S., & Dhiman, R. K. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/s0973-6883(12)60115-7 · Cited by 1
Association polyarthrite rhumatoïde et cirrhose biliaire primitive
Caramella, C., Avouac, J., Sogni, P., Puéchal, X., Kahan, A., & Allanore, Y. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2006.06.017 · Cited by 1
“[3] Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, et al.”
BackgroundAutoimmune cholangitis, nosological location.
Sánchez-Pobre, P., & Solis-Herruzo, J. A. (2003) · PubMed · Cited by 4
Enfermedades colest?sicas cr?nicas
Chaparro, M., Moreno-Monteagudo, J. A., Garca-Buey, L. C., & Moreno‐Otero, R. (2008) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(08)73154-0 · Cited by 1
Primäre biliäre Zirrhose - Eine Falldarstellung. Primary Biliary Cirrhosis - a Case Report
Sägers, A., Tromm, A., Weißer, H., & Krieg, M. (1999) · Journal of Laboratory Medicine · doi:10.1515/labm.1999.23.10.556
“Auch zwischen -positiven und -negativen Patienten mit jeweils histologisch gesicherter PBC konnten keine signifikanten Unterschiede hinsichtlich der klinischen Symptome sowie des individuellen Krankheitsverlaufs nachgewiesen werden [14, 15].”
BackgroundBiologie des maladies cholestatiques chroniques de l’adulte
Lemoinne, S., & Chazouillères, O. (2017) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(17)30077-1
Hasui, H., NISHIMURA, K., Izumori, A., Yositeru, K. A. J. I., & Satou, A. (2005) · Kanzo · doi:10.2957/kanzo.46.563
P2 B cell depletion therapy exacerbates murine primary biliary cirrhosis
Lleò, A., Bernuzzi, F., Moroni, L., Bianchi, I., DUNN, R. C., Kehry, M. R., Packard, T. A., Cambier, J. C., Podda, M., Gershwin, M. E., et al. (2010) · Digestive and Liver Disease · doi:10.1016/s1590-8658(10)60536-1
Self-citationNon-PBC, Non-PSC autoimmune cholangiopathy
Mayo, M. J. (2000) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-000-0005-z
Primary Biliary Cirrhosis: Present and Future
Trianos, C., & Avgerinos, A. (2006) · Annals of Gastroenterology
Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis
Kim, J., Kim, T. H., Yoo, K., Han, Y. J., Choi, J. E., Kim, J. Y., & Cho, M.-S. (2015) · Ewha Medical Journal · doi:10.12771/emj.2015.38.3.106
“기존 연구에서 AMA 양성 PBC와 AMA 음성 PBC의 임상경과 및 UDCA에 대한 치료반응이 유사하다고 보고 되는데[14,15], 본 연구에서도 AMA 양성여부에 따라 나누어 치료 반응률을 계산하 였을 때, AMA 음성군에서 AMA 양성군에 비해 높은 치료 반응 률을 보이는 경향이 있었으나 통계적으로 유의한 차이는 나타나지 않았다.”
Maladies auto-immunes des voies biliaires
Chazouillères, O. (2001) · Gastroentérologie Clinique et Biologique · Cited by 2
A case of polymyositis concomitant with primary biliary cirrhosis simultaneously
Yokosuka, J., Ishikawa, T., Nakao, Y., Saruta, M., Hokari, A., Koike, K., Kitahara, T., Harada, T., Hano, H., & Tajiri, H. (2012) · Kanzo · doi:10.2957/kanzo.53.216
Overlap Syndromes of Primary Sclerosing Cholangitis
Czaja, A. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-40908-5_4
Challenges and opportunities in the management of portal hypertension
Patanwala, I. (2015)
Serological tests for primary biliary cholangitis
Aralica, M., Giljača, V., Poropat, G., Hauser, G., & Štimac, D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012560
Carey, E. J., & Levy, C. (2018) · Clinics in Liver Disease · doi:10.1016/s1089-3261(18)30044-8 · Cited by 1
Caramella, C., Avouac, J., Sogni, P., Puéchal, X., Kahan, A., & Allanore, Y. (2007)
Soluble adenylyl cyclase : A regulator of intrinsic cellular functions
Chang, J. (2018) · UvA-DARE (University of Amsterdam)
Diseases of the Liver: Primary Biliary Cholangitis
Phillips, P. K., & Said, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-25626-5_7
Managing Acute and Chronic Seronegative Liver Disease
Robertson, M. C., & Hayes, P. C. (2020) · Wiley eBooks · doi:10.1002/9781119532637.ch10
Heathcote, E. J. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50048-6
Hirschfield, G. M., & Heathcote, E. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00043-7
Primary Biliary Cholangitis: Autoimmune Hepatitis Overlap Syndrome
Cazzagon, N., & Chazouillères, O. (2020) · Springer eBooks · doi:10.1007/978-3-030-51709-0_24
Chaltsev, B. D., Vasiliev, V., Palshina, S. G., Torgashina, A. V., Sokol, E., Khvan, Y. I., Rodionova, E. B., Safonova, T. N., & Некрасова, Т. П. (2021) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2021-3-27-34
Autoantibodies in Primary Biliary Cirrhosis
Komori, A. (2014) · Springer eBooks · doi:10.1007/978-4-431-54789-1_17
“[3 8 ] 2 0 1 0 G re ek 1 4 7 A ll 8 9 .”
BackgroundInfluentialMcFarlane, I. G. (2000) · Springer eBooks · doi:10.1007/978-94-011-4000-3_6 · Cited by 1
Dancygier, H. (2003) · Springer eBooks · doi:10.1007/978-3-642-55902-0_25
Clinicopathological and Imaging Features of Primary Biliary CholangitisPreprint
Xie, M., Nyabanga, C. T. T., Sehmbhi, M., Khalili, N. A., Chon, C., Kamath, A., Dinani, A. M., & Weisberg, I. S. (2022) · medRxiv · doi:10.1101/2022.04.29.22274511 · Cited by 1
Yao, T.-T., Qian, J., & Wang, G. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.03.007
Diagnosis of primary biliary liver diseases, overlap syndromes and changing diagnoses
Heathcote, J. (2007) · Springer eBooks · doi:10.1007/1-4020-2914-4_16
Primary biliary cirrhosis and biliary destruction: 2005; a liver odyssey
Oertelt‐Prigione, S., Selmi, C. F., Invernizzi, P., Podda, M., Coppel, R. L., & Gershwin, M. E. (2007) · Springer eBooks · doi:10.1007/1-4020-4144-6_18
Self-citationAnswers to Multiple Choice Questions
Agrawal, S., & Dhiman, R. K. (2012) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2012.10.007
Beuers, U. H. (2007) · Wiley eBooks · doi:10.1002/9780470691861.ch11e
Khakoo, N. S., & Levy, C. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-23947-2.00039-4
Leung, P. S. C., Manns, M. P., Coppel, R. L., & Gershwin, M. E. (2024) · Wiley eBooks · doi:10.1002/9781683674023.ch94
Primär biliäre Cholangitis – Update zu Diagnostik, Risikostratifizierung und neuen Therapieoptionen
Herta, T., & Berg, T. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01988-0
Suchowiecki, K., & Wu, G. Y. (2026) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2026.00117
Metadata
- Authors
- Invernizzi, P., Crosignani, A., Battezzati, P. M., Covini, G., De Valle, G., Larghi, A., Zuin, M., & Podda, M.
- Affiliations
- Ospedale San Paolo (IT)
- Venue
- Hepatology
- Published
- 1997-05
- Volume
- 25
- Issue
- 5
- Pages
- 1090-1095
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W1994218082
- Cited by
- 293
- References
- 18
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 5 · 2022: 5 · 2021: 7 · 2020: 7 · 2019: 4 · 2018: 7 · 2017: 8 · 2016: 5 · 2015: 10 · 2014: 11 · 2013: 6 · 2012: 18
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6697 d)
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- primary biliary cirrhosis, antimitochondrial antibodies, antinuclear antibodies, anti-smooth muscle antibodies, non-organ-specific autoantibodies, clinical course, cirrhosis complications, liver failure, liver transplantation, cholestatic liver disease
- MeSH terms
- Adult, Aged, Autoantibodies, Female, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Mitochondria, Prognosis, Autoimmunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.